BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Efeckta Introduces Proteomics Tools Suite Software To Improved Protein Identification At Mass Spectrometry Conference: ProTS-Data Now Available


10/19/2005 5:11:28 PM

STEAMBOAT SPRINGS, Colo., May 24 /PRNewswire/ -- Efeckta Technologies Corporation (http://www.efeckta.com/) announced today, at the Annual Meeting of the American Society of Mass Spectrometry (ASMS) in Nashville, TN, that ProTS-Data has been released for commercial sale.

ProTS-Data is an automated software program used in the analysis of raw data associated with mass spectrometry based proteomics research. Mass spectrometry (MS) has become the method of choice for the identification and characterization of proteins and peptides for drug discovery and diagnostic marker identification applications.

According to Dr. Heinrich Roder, Efeckta's Chief Technical Officer, "We believe that powerful software capable of translating mass spectral data to accurate protein and peptide identifications is required in order to realize the full potential of the new generation of mass spectrometers. The performance functionality of ProTS-Data is focused on this defined need in proteomics-based mass spectrometry."

ProTS-Data is differentiated from competitive products in several significant ways. Among its features are proprietary algorithms that can remove interfering background noise from datasets to provide more precise and accurate peptide peak detection results. This in turn can lead to improved protein identification and the elimination of false positive information supplied by other software.

"Researchers who have used ProTS-Data are presenting studies comparing our proprietary software to their current MS software at the ASMS. They are reporting improved accuracy, reliability and significant time savings," said Dr. Roder. "Our academic and commercial clients and developmental partners have validated improved research results using ProTS-Data."

"Visual inspection of all peaks that matched to potential peptides showed that ProTS-Data and manual assignment yield similar lists and provided more accurate search results when compared to other software," said Dr. LeeAnn Higgins of the Univ. of Minnesota.

ProTS-Data is the second in a series of software products being developed by Efeckta designed to enhance the accuracy and efficiency of information and knowledge capture from large, complex mass spectrometry datasets. "We are confident that researchers around the world will want to use the best protein identification software available. As part of our new product introduction, a free 30-day trial of Efeckta's ProTS-Data software is available at http://www.efeckta.com/," said Dr. Roder.

Efeckta Technologies Corporation is a privately held, science-oriented software development company located in Steamboat Springs, Colorado. Efeckta's primary area of expertise is in the development of diverse data management and analysis toolsets based on rigorous application of proprietary mathematical techniques. The company's current technology and market focus is in the proteomics and mass spectrometry segments of the Life Sciences market.

For further information, please contact: Charlie Parnell, Vice President, Efeckta Sales, 970-870-2844, x125, 970-879-8523 - fax or info@efeckta.com.

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com/.

Efeckta Technologies Corporation

CONTACT: Charlie Parnell, Vice President, Efeckta Sales,+1-970-870-2844, x125, +1-970-879-8523 - fax, or info@efeckta.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES